Highlights Newsletter 2
This newsletter presents you the following key sessions:
- Watch the video interview with professor E. van Cutsem about the AGITG ICECREAM trial evaluating the role of cetuximab in patients with KRAS G13D mutated colorectal cancer
- Cabozantinib slows disease progression in patients with advanced kidney cancer
- Nivolumab combined with ipilimumab delays disease progression in advanced melanoma, regardless of genetic status, age and disease stage
- Nivolumab increases the 1-year survival rate in patients with non-squamous non-small cell lung cancer
- 177Lu-Dotatate delays disease progression in gastrointestinal neuroendocrine tumors